Skip to content
Peptide Therapeutics intermediate

Milestone 011: Oligopeptide Research Reference

2003: First anti-TNF biologic (adalimumab) approved. Opens era of biologic immunotherapy. This peptide or oligopeptide is studied for its biological activity...

By Encyclopeptide Editorial | 1 min read
milestone-011 peptide research

Overview

2003: First anti-TNF biologic (adalimumab) approved. Opens era of biologic immunotherapy.

Clinical Significance

This topic has important implications for peptide research and clinical applications.

References

  1. Encyclopeptide Database. “Milestone 011” monograph. encyclopeptide.com.

Test Your Knowledge

Reinforce what you learned about Milestone 011: Oligopeptide Research Reference with interactive quizzes on Wikipept.

Take a Quiz on Wikipept